Investigational tolebrutinib slowed disability progression in people with non-relapsing secondary progressive multiple ...

Tolebrutinib is an oral, brain-penetrant, and bioactive Bruton’s tyrosine kinase inhibitor that modulates peripheral ...

Throughout the course of multiple sclerosis, gradually progressive neurologic impairment can occur, which has been called ...

Annual Meeting Clinical Trials Plenary Session, Sanofi presented data on tolebrutinib in patients with non-relapsing ...

Tolebrutinib, a novel BTK inhibitor that targets neuroinflammation, slowed disability progression by 31% in nrSPMS, a phase 3 ...

Tolebrutinib, a brain-penetrant BTK inhibitor, may fill a significant unmet need by delaying disability progression in patients with non-relapsing secondary progressive multiple sclerosis.

Tolebrutinib was found to delay disability progression in people with nonrelapsing secondary progressive MS in a Phase 3 ...

Experimental drug shows promise for advanced MS, delaying disability. Learn how Black Americans may benefit & why clinical ...

A Cleveland Clinic-led clinical trial of tolebrutinib, an investigational oral Bruton’s tyrosine kinase inhibitor, a group of drugs originally developed to treat lymphomas and related blood disorders, ...

Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosisResults from the HERCULES phase 3 ...

At the American Academy of Neurology (AAN) 2025 Annual Meeting Clinical Trials Plenary Session, Sanofi presented data on tolebrutinib in patients with non-relapsing secondary progressive multiple ...